{
    "clinical_study": {
        "@rank": "1570", 
        "acronym": "Carnorisk", 
        "arm_group": [
            {
                "arm_group_label": "CARNOSINE", 
                "arm_group_type": "Experimental", 
                "description": "3 months oral carnosine administration in a dose of 2 gram per day, twice a day 1 gram dose (1-0-1)"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "3 months placebo intake - taken twice a day (1-0-1)"
            }
        ], 
        "brief_summary": {
            "textblock": "Carnosine is a naturally occurring compound with a potential health benefits. In animal\n      studies, carnosine supplementation reduces manifestation of chronic civilization diseases,\n      regulates subclinical inflammation, protein glycation and lipid & glucose metabolism. Our\n      preliminary data showed the relationship between insulin resistance and carnosine content in\n      human skeletal muscle. Based on these unique results we plan to perform intervention study\n      aimed at identifying effects of carnosine on insulin sensitivity and secretion, which might\n      reduce the development of T2D in obese. Similar metabolic effects of vitamin D3 were\n      associated with expression of specific miRNAs. Circulating miRNAs related to carnosine\n      action are unknown. The putative positive effects of carnosine on insulin sensitivity and\n      secretion in obese patients might have a tremendous impact in prevention of type 2 diabetes.\n      Identification of miRNAs associated with carnosine action could provide predictors of\n      successful therapy."
        }, 
        "brief_title": "Effect of Carnosine on Diabetes and Cardiovascular Risk Factors", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Metabolic Diseases, Type 2 Diabetes, Cardiovascular Disease", 
        "condition_browse": {
            "mesh_term": [
                "Cardiovascular Diseases", 
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Metabolic Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  BMI (28-38 kg.m-2);\n\n          -  waist circumference >94 cm;\n\n          -  % body fat 30%\n\n          -  fasting glycemia < 7 mmol/l\n\n        Exclusion Criteria:\n\n          -  age < 25 or > 50 years,\n\n          -  change in body weight > 5 kg in last 12 months,\n\n          -  obesity with BMI > 38kg.m-2,\n\n          -  previously or newly (oGTT) diagnosed type 2 diabetes,\n\n          -  allergy, smoking, alcohol abuse, any pharmacotherapy including regular vitamin\n             intake;\n\n          -  cardiovascular, hematologic, respiratory, gastrointestinal, endocrine or oncologic\n             diseases,\n\n          -  kidney disease, acute inflammatory disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02011100", 
            "org_study_id": "CarnoDMCVD"
        }, 
        "intervention": {
            "arm_group_label": "CARNOSINE", 
            "intervention_name": "Carnosine", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 12, 2013", 
        "location": [
            {
                "contact": {
                    "email": "barbara.ukropcova@savba.sk", 
                    "last_name": "Barbara Ukropcova, MD, PhD", 
                    "phone": "+421-2-5477-2800", 
                    "phone_ext": "254"
                }, 
                "facility": {
                    "address": {
                        "city": "Bratislava", 
                        "country": "Slovakia", 
                        "zip": "83306"
                    }, 
                    "name": "Institute of Experimental Endocrinology Slovak Academy of Sciences"
                }, 
                "investigator": [
                    {
                        "last_name": "Jozef Ukropec, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Michaela Jakubova, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Barbara Ukropcova, MD, PhD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "boris.krahulec@sm.unb.sk", 
                    "last_name": "Boris Krahulec, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bratislava", 
                        "country": "Slovakia", 
                        "zip": "81369"
                    }, 
                    "name": "Univeristy Hospital in Bratislava"
                }, 
                "investigator": {
                    "last_name": "Boris Krahulec, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Slovakia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomised Placebo Controlled Study of the Effect of Carnosine Diabetes and Cardiovascular Risk Factors", 
        "other_outcome": {
            "description": "assessed by 1H-MRS  of muscle in vivo (7T Magnet, Siemens, Germany) it will be expressed relative to creatine signal.", 
            "measure": "muscle carnosine content", 
            "safety_issue": "No", 
            "time_frame": "within 9 months"
        }, 
        "overall_contact": {
            "email": "barbara.ukropcova@savba.sk", 
            "last_name": "Barbara Ukropcova, MD, PhD", 
            "phone": "+421-2-5477-2800", 
            "phone_ext": "254"
        }, 
        "overall_contact_backup": {
            "email": "jozef.ukropec@savba.sk", 
            "last_name": "Jozef Ukropec, PhD", 
            "phone": "+421-2-5477-2800", 
            "phone_ext": "205"
        }, 
        "overall_official": [
            {
                "affiliation": "Institute of experimental endocrinology SAS", 
                "last_name": "Jozef Ukropec, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Faculty of Medicine Comenius University & Institute of Experimental Endocrinology SAS", 
                "last_name": "Barbara Ukropcova, MD, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "University Hospital in Bratislava", 
                "last_name": "Boris Krahulec, MD, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Slovak Republic: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "AGEs and lipid peroxidation products", 
                "measure": "oxidative stress", 
                "safety_issue": "No", 
                "time_frame": "within one year"
            }, 
            {
                "description": "circulating hsCRP", 
                "measure": "chronic systemic inflammation", 
                "time_frame": "one year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02011100"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Slovak Academy of Sciences", 
            "investigator_full_name": "Jozef Ukropec", 
            "investigator_title": "PhD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "detected by the oral glucose tolerance test. expressed as 2h glucose, area under the glycemic curve, QUICKI index, HOMA-IR", 
            "measure": "level of glucose intolerance", 
            "safety_issue": "No", 
            "time_frame": "within 10 months"
        }, 
        "source": "Slovak Academy of Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jozef Ukropec", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}